首页 > 最新文献

PharmacoEconomics最新文献

英文 中文
Comparing the Psychometric Performance of Generic Paediatric Health-Related Quality of Life Instruments in Children and Adolescents with ADHD, Anxiety and/or Depression. 比较通用儿科健康相关生活质量工具在多动症、焦虑症和/或抑郁症儿童和青少年中的心理测量性能。
IF 4.4 3区 医学 Q1 Medicine Pub Date : 2024-06-01 Epub Date: 2024-02-08 DOI: 10.1007/s40273-024-01354-2
Rachel O'Loughlin, Renee Jones, Gang Chen, Brendan Mulhern, Harriet Hiscock, Nancy Devlin, Kim Dalziel

Objective: The aim of this study was to examine the validity, reliability and responsiveness of common generic paediatric health-related quality of life (HRQoL) instruments in children and adolescents with mental health challenges.

Methods: Participants were a subset of the Australian Paediatric Multi-Instrument Comparison (P-MIC) study and comprised 1013 children aged 4-18 years with attention-deficit/hyperactivity disorder (ADHD) (n = 533), or anxiety and/or depression (n = 480). Participants completed an online survey including a range of generic paediatric HRQoL instruments (PedsQL, EQ-5D-Y-3L, EQ-5D-Y-5L, CHU9D) and mental health symptom measures (SDQ, SWAN, RCADS-25). A subset of participants also completed the HUI3 and AQoL-6D. The psychometric performance of each HRQoL instrument was assessed regarding acceptability/feasibility; floor/ceiling effects; convergent validity; known-group validity; responsiveness and test-retest reliability.

Results: The PedsQL, CHU9D, EQ-5D-Y-3L and EQ-5D-Y-5L showed similarly good performance for acceptability/feasibility, known-group validity and convergent validity. The CHU9D and PedsQL showed no floor or ceiling effects and fair-good test-retest reliability. Test-retest reliability was lower for the EQ-5D-Y-3L and EQ-5D-Y-5L. The EQ-5D-Y-3L showed the highest ceiling effects, but was the top performing instrument alongside the CHU9D on responsiveness to improvements in health status, followed by the PedsQL. The AQoL-6D and HUI3 showed good acceptability/feasibility, no floor or ceiling effects, and good convergent validity, yet poorer performance on known-group validity. Responsiveness and test-retest reliability were not able to be assessed for these two instruments. In subgroup analyses, performance was similar for all instruments for acceptability/feasibility, known-group and convergent validity, however, relative strengths and weaknesses for each instrument were noted for ceiling effects, responsiveness and test-retest reliability. In sensitivity analyses using utility scores, performance regarding known-group and convergent validity worsened slightly for the EQ-5D-Y-3L and CHU9D, though improved slightly for the HUI3 and AQoL-6D.

Conclusions: While each instrument showed strong performance in some areas, careful consideration of the choice of instrument is advised, as this may differ dependent on the intended use of the instrument, and the age, gender and type of mental health condition of the population in which the instrument is being used.

Trial registration: ANZCTR-ACTRN12621000657820.

研究目的本研究的目的是检验常见的儿科健康相关生活质量(HRQoL)通用工具在有心理健康问题的儿童和青少年中的有效性、可靠性和响应性:参与者是澳大利亚儿科多工具比较(P-MIC)研究的一个子集,包括 1013 名 4-18 岁患有注意力缺陷/多动症(ADHD)(n = 533)或焦虑症和/或抑郁症(n = 480)的儿童。参与者完成了一项在线调查,包括一系列通用儿科 HRQoL 工具(PedsQL、EQ-5D-Y-3L、EQ-5D-Y-5L、CHU9D)和心理健康症状测量(SDQ、SWAN、RCADS-25)。一部分参与者还完成了 HUI3 和 AQoL-6D。对每种 HRQoL 工具的心理测量性能进行了评估,包括可接受性/可行性、上下限效应、收敛效度、已知组效度、响应性和重复测试可靠性:结果: PedsQL、CHU9D、EQ-5D-Y-3L 和 EQ-5D-Y-5L 在可接受性/可行性、已知组有效性和收敛有效性方面表现类似。CHU9D 和 PedsQL 没有显示出下限或上限效应,测试-再测可靠性尚可。EQ-5D-Y-3L和EQ-5D-Y-5L的重测可靠性较低。EQ-5D-Y-3L的上限效应最高,但在对健康状况改善的反应性方面,它与CHU9D一样是表现最好的工具,其次是PedsQL。AQoL-6D 和 HUI3 显示出良好的可接受性/可行性、无下限效应或上限效应、良好的收敛效度,但在已知组效度方面表现较差。这两种工具的反应性和重复测试可靠性无法评估。在分组分析中,所有工具在可接受性/可行性、已知组和收敛效度方面的表现相似,但在上限效应、响应性和重复测试可靠性方面,每种工具都有相对的优势和劣势。在使用效用分数进行的敏感性分析中,EQ-5D-Y-3L 和 CHU9D 在已知组和收敛有效性方面的表现略有恶化,而 HUI3 和 AQoL-6D 则略有改善:结论:虽然每种工具在某些方面都有很好的表现,但建议在选择工具时要慎重考虑,因为这可能会因工具的预期用途、使用人群的年龄、性别和精神健康状况类型而有所不同:ANZCTR-ACTRN12621000657820.
{"title":"Comparing the Psychometric Performance of Generic Paediatric Health-Related Quality of Life Instruments in Children and Adolescents with ADHD, Anxiety and/or Depression.","authors":"Rachel O'Loughlin, Renee Jones, Gang Chen, Brendan Mulhern, Harriet Hiscock, Nancy Devlin, Kim Dalziel","doi":"10.1007/s40273-024-01354-2","DOIUrl":"10.1007/s40273-024-01354-2","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to examine the validity, reliability and responsiveness of common generic paediatric health-related quality of life (HRQoL) instruments in children and adolescents with mental health challenges.</p><p><strong>Methods: </strong>Participants were a subset of the Australian Paediatric Multi-Instrument Comparison (P-MIC) study and comprised 1013 children aged 4-18 years with attention-deficit/hyperactivity disorder (ADHD) (n = 533), or anxiety and/or depression (n = 480). Participants completed an online survey including a range of generic paediatric HRQoL instruments (PedsQL, EQ-5D-Y-3L, EQ-5D-Y-5L, CHU9D) and mental health symptom measures (SDQ, SWAN, RCADS-25). A subset of participants also completed the HUI3 and AQoL-6D. The psychometric performance of each HRQoL instrument was assessed regarding acceptability/feasibility; floor/ceiling effects; convergent validity; known-group validity; responsiveness and test-retest reliability.</p><p><strong>Results: </strong>The PedsQL, CHU9D, EQ-5D-Y-3L and EQ-5D-Y-5L showed similarly good performance for acceptability/feasibility, known-group validity and convergent validity. The CHU9D and PedsQL showed no floor or ceiling effects and fair-good test-retest reliability. Test-retest reliability was lower for the EQ-5D-Y-3L and EQ-5D-Y-5L. The EQ-5D-Y-3L showed the highest ceiling effects, but was the top performing instrument alongside the CHU9D on responsiveness to improvements in health status, followed by the PedsQL. The AQoL-6D and HUI3 showed good acceptability/feasibility, no floor or ceiling effects, and good convergent validity, yet poorer performance on known-group validity. Responsiveness and test-retest reliability were not able to be assessed for these two instruments. In subgroup analyses, performance was similar for all instruments for acceptability/feasibility, known-group and convergent validity, however, relative strengths and weaknesses for each instrument were noted for ceiling effects, responsiveness and test-retest reliability. In sensitivity analyses using utility scores, performance regarding known-group and convergent validity worsened slightly for the EQ-5D-Y-3L and CHU9D, though improved slightly for the HUI3 and AQoL-6D.</p><p><strong>Conclusions: </strong>While each instrument showed strong performance in some areas, careful consideration of the choice of instrument is advised, as this may differ dependent on the intended use of the instrument, and the age, gender and type of mental health condition of the population in which the instrument is being used.</p><p><strong>Trial registration: </strong>ANZCTR-ACTRN12621000657820.</p>","PeriodicalId":19807,"journal":{"name":"PharmacoEconomics","volume":" ","pages":"57-77"},"PeriodicalIF":4.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11168999/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139703042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective. 在 NICE 对 Pembrolizumab 用于 MSI-H/dMMR 实体瘤的单一技术评估中,对组织学无关的事件发生时间结果进行贝叶斯分层建模:外部评估小组的观点。
IF 4.4 3区 医学 Q1 Medicine Pub Date : 2024-06-01 Epub Date: 2024-05-07 DOI: 10.1007/s40273-024-01381-z
Bradley M Sugden, Sabine E Grimm, Robert Wolff, Nigel Armstrong, Thomas Otten, Teebah Abu-Zahra, Mark Perry, Mubarak Patel, Jiongyu Chen, Caro Noake, Manuela Joore, Willem J A Witlox
{"title":"Bayesian Hierarchical Modelling for Histology-Independent Time-to-Event Outcomes in the NICE Single Technology Appraisal of Pembrolizumab for Solid Tumours with MSI-H/dMMR: External Assessment Group Perspective.","authors":"Bradley M Sugden, Sabine E Grimm, Robert Wolff, Nigel Armstrong, Thomas Otten, Teebah Abu-Zahra, Mark Perry, Mubarak Patel, Jiongyu Chen, Caro Noake, Manuela Joore, Willem J A Witlox","doi":"10.1007/s40273-024-01381-z","DOIUrl":"10.1007/s40273-024-01381-z","url":null,"abstract":"","PeriodicalId":19807,"journal":{"name":"PharmacoEconomics","volume":" ","pages":"615-618"},"PeriodicalIF":4.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11126505/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140864695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Market Transparency in Medicine Pricing: Pathways to Fair Pricing. 医药定价的市场透明度:公平定价之路》。
IF 4.4 3区 医学 Q1 ECONOMICS Pub Date : 2024-06-01 Epub Date: 2024-05-09 DOI: 10.1007/s40273-024-01390-y
João L Carapinha
{"title":"Market Transparency in Medicine Pricing: Pathways to Fair Pricing.","authors":"João L Carapinha","doi":"10.1007/s40273-024-01390-y","DOIUrl":"10.1007/s40273-024-01390-y","url":null,"abstract":"","PeriodicalId":19807,"journal":{"name":"PharmacoEconomics","volume":" ","pages":"611-614"},"PeriodicalIF":4.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140898552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Validity of the EuroQol Health and Wellbeing Short Version (EQ-HWB-S) Instrument in Parents of Children With and Without Health Conditions. 有健康问题和无健康问题儿童的家长使用 EuroQol 健康与幸福简易版 (EQ-HWB-S) 工具的有效性。
IF 4.4 3区 医学 Q1 Medicine Pub Date : 2024-06-01 Epub Date: 2024-01-18 DOI: 10.1007/s40273-024-01351-5
Cate Bailey, Kim Dalziel, Renee Jones, Harriet Hiscock, Nancy J Devlin, Tessa Peasgood

Background:  The EuroQol Health and Wellbeing Short Version (EQ-HWB-S) instrument has been developed to measure the health and wellbeing of care-recipients and their caregivers for use in economic evaluation.The EQ-HWB-S has nine items, and pilot UK preference weights have now been developed.

Objective: We aimed to investigate the validity of the instrument in parents of children with and without health conditions.

Methods: EQ-HWB-S data were sourced from an Australian paediatric multi-instrument comparison study. We analysed the baseline characteristics and response distribution of the EQ-HWB-S items. Assessment of known-group validity was conducted for EQ-HWB-S items, level sum-scores and preference-weighted scores, including partial effects. Known-group analyses included three child health variables and where caregivers reported coronavirus disease 2019 (COVID-19) had impacted their wellbeing. We included analyses across gender, controlled for child and parent demographic variables, and compared scores across child health conditions.

Results:  Item responses were distributed as expected, with higher skew for mobility and activities. Parents experienced high levels of exhaustion. We detected significant differences between groups for level sum-scores and preference-weighted scores, as hypothesised; all tests were significant (p < 0.001), with moderate effect sizes (effect sizes were slightly higher for female than male parents). The regression analysis identified significantly different EQ-HWB-S scores for child health samples compared with the general population after controlling for demographic variables. Differences were observed between child health conditions.

Conclusion: The EQ-HWB-S is a useful instrument to measure parent quality of life for economic evaluation in this population. Data were limited to one time point; further research should investigate the instrument's sensitivity to change and test-retest reliability in this population.

背景: EQ-HWB-S共有9个项目,目前已开发出英国试点偏好权重:我们旨在调查该工具在有健康问题和无健康问题儿童的父母中的有效性:方法:EQ-HWB-S 数据来源于一项澳大利亚儿科多工具比较研究。我们分析了 EQ-HWB-S 项目的基线特征和反应分布。我们对 EQ-HWB-S 项目、水平总分和偏好加权分数(包括部分效应)进行了已知组有效性评估。已知组分析包括三个儿童健康变量以及护理人员报告冠状病毒疾病2019(COVID-19)对其福祉产生影响的情况。我们进行了跨性别分析,控制了儿童和家长的人口统计学变量,并比较了不同儿童健康状况下的得分: 结果:项目回答的分布符合预期,行动能力和活动能力的得分偏高。家长的疲惫程度较高。正如假设的那样,我们在水平总分和偏好加权得分方面发现了组间的显著差异;所有测试结果均有显著性(p 结论:EQ-HWB-S 是一项针对儿童健康状况的量表:EQ-HWB-S 是测量家长生活质量的有用工具,可用于对该人群进行经济评估。数据仅限于一个时间点;进一步的研究应调查该工具在该人群中对变化的敏感性和测试-再测试的可靠性。
{"title":"The Validity of the EuroQol Health and Wellbeing Short Version (EQ-HWB-S) Instrument in Parents of Children With and Without Health Conditions.","authors":"Cate Bailey, Kim Dalziel, Renee Jones, Harriet Hiscock, Nancy J Devlin, Tessa Peasgood","doi":"10.1007/s40273-024-01351-5","DOIUrl":"10.1007/s40273-024-01351-5","url":null,"abstract":"<p><strong>Background: </strong> The EuroQol Health and Wellbeing Short Version (EQ-HWB-S) instrument has been developed to measure the health and wellbeing of care-recipients and their caregivers for use in economic evaluation.The EQ-HWB-S has nine items, and pilot UK preference weights have now been developed.</p><p><strong>Objective: </strong>We aimed to investigate the validity of the instrument in parents of children with and without health conditions.</p><p><strong>Methods: </strong>EQ-HWB-S data were sourced from an Australian paediatric multi-instrument comparison study. We analysed the baseline characteristics and response distribution of the EQ-HWB-S items. Assessment of known-group validity was conducted for EQ-HWB-S items, level sum-scores and preference-weighted scores, including partial effects. Known-group analyses included three child health variables and where caregivers reported coronavirus disease 2019 (COVID-19) had impacted their wellbeing. We included analyses across gender, controlled for child and parent demographic variables, and compared scores across child health conditions.</p><p><strong>Results: </strong> Item responses were distributed as expected, with higher skew for mobility and activities. Parents experienced high levels of exhaustion. We detected significant differences between groups for level sum-scores and preference-weighted scores, as hypothesised; all tests were significant (p < 0.001), with moderate effect sizes (effect sizes were slightly higher for female than male parents). The regression analysis identified significantly different EQ-HWB-S scores for child health samples compared with the general population after controlling for demographic variables. Differences were observed between child health conditions.</p><p><strong>Conclusion: </strong>The EQ-HWB-S is a useful instrument to measure parent quality of life for economic evaluation in this population. Data were limited to one time point; further research should investigate the instrument's sensitivity to change and test-retest reliability in this population.</p>","PeriodicalId":19807,"journal":{"name":"PharmacoEconomics","volume":" ","pages":"163-179"},"PeriodicalIF":4.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11168993/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139491776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lessons Learned from Model-based Economic Evaluations of COVID-19 Drug Treatments Under Pandemic Circumstances: Results from a Systematic Review. 在大流行情况下对 COVID-19 药物治疗进行基于模型的经济评估的经验教训:系统回顾的结果。
IF 4.4 3区 医学 Q1 ECONOMICS Pub Date : 2024-06-01 Epub Date: 2024-05-10 DOI: 10.1007/s40273-024-01375-x
Clazinus Veijer, Marinus H van Hulst, Benjamin Friedrichson, Maarten J Postma, Antoinette D I van Asselt

Background: Following clinical research of potential coronavirus disease 2019 (COVID-19) treatments, numerous decision-analytic models have been developed. Due to pandemic circumstances, clinical evidence was limited and modelling choices were made under great uncertainty. This study aimed to analyse key methodological characteristics of model-based economic evaluations of COVID-19 drug treatments, and specifically focused on modelling choices which pertain to disease severity levels during hospitalisation, model structure, sources of effectiveness and quality of life and long-term sequelae.

Methods: We conducted a systematic literature review and searched key databases (including MEDLINE, EMBASE, Web of Science, Scopus) for original articles on model-based full economic evaluations of COVID-19 drug treatments. Studies focussing on vaccines, diagnostic techniques and non-pharmaceutical interventions were excluded. The search was last rerun on 22 July 2023. Results were narratively synthesised in tabular form. Several aspects were categorised into rubrics to enable comparison across studies.

Results: Of the 1047 records identified, 27 were included, and 23 studies (85.2%) differentiated patients by disease severity in the hospitalisation phase. Patients were differentiated by type of respiratory support, level of care management, a combination of both or symptoms. A Markov model was applied in 16 studies (59.3%), whether or not preceded by a decision tree or an epidemiological model. Most cost-utility analyses lacked the incorporation of COVID-19-specific health utility values. Of ten studies with a lifetime horizon, seven adjusted general population estimates to account for long-term sequelae (i.e. mortality, quality of life and costs), lasting for 1 year, 5 years, or a patient's lifetime. The most often reported parameter influencing the outcome of the analysis was related to treatment effectiveness.

Conclusion: The results illustrate the variety in modelling approaches of COVID-19 drug treatments and address the need for a more standardized approach in model-based economic evaluations of infectious diseases such as COVID-19.

Trial registry: Protocol registered in PROSPERO under CRD42023407646.

背景:在对 2019 年冠状病毒病(COVID-19)的潜在治疗方法进行临床研究之后,开发了许多决策分析模型。由于大流行的情况,临床证据有限,模型选择具有很大的不确定性。本研究旨在分析基于模型的 COVID-19 药物治疗经济评价的主要方法学特征,并特别关注与住院期间疾病严重程度、模型结构、有效性来源以及生活质量和长期后遗症有关的建模选择:我们进行了系统的文献综述,并在主要数据库(包括 MEDLINE、EMBASE、Web of Science、Scopus)中检索了有关 COVID-19 药物治疗基于模型的全面经济评估的原创文章。以疫苗、诊断技术和非药物干预为重点的研究被排除在外。最后一次重新搜索是在 2023 年 7 月 22 日。搜索结果以表格形式进行了叙述性综合。为便于对不同研究进行比较,还将几个方面归类为评分标准:在确定的 1047 份记录中,有 27 份被纳入,23 项研究(85.2%)在住院阶段根据疾病严重程度对患者进行了区分。根据呼吸支持类型、护理管理水平、两者的组合或症状对患者进行了区分。有 16 项研究(59.3%)采用了马尔可夫模型,无论之前是否有决策树或流行病学模型。大多数成本效用分析未纳入 COVID-19 特异性健康效用值。在 10 项以终生为视角的研究中,有 7 项研究调整了普通人群的估计值,以考虑长期后遗症(即死亡率、生活质量和成本),持续时间为 1 年、5 年或患者终生。最常报告的影响分析结果的参数与治疗效果有关:结果表明,COVID-19 药物治疗的建模方法多种多样,因此在对 COVID-19 等传染病进行基于模型的经济评估时,需要采用更加标准化的方法:试验方案已在 PROSPERO 登记,编号为 CRD42023407646。
{"title":"Lessons Learned from Model-based Economic Evaluations of COVID-19 Drug Treatments Under Pandemic Circumstances: Results from a Systematic Review.","authors":"Clazinus Veijer, Marinus H van Hulst, Benjamin Friedrichson, Maarten J Postma, Antoinette D I van Asselt","doi":"10.1007/s40273-024-01375-x","DOIUrl":"10.1007/s40273-024-01375-x","url":null,"abstract":"<p><strong>Background: </strong>Following clinical research of potential coronavirus disease 2019 (COVID-19) treatments, numerous decision-analytic models have been developed. Due to pandemic circumstances, clinical evidence was limited and modelling choices were made under great uncertainty. This study aimed to analyse key methodological characteristics of model-based economic evaluations of COVID-19 drug treatments, and specifically focused on modelling choices which pertain to disease severity levels during hospitalisation, model structure, sources of effectiveness and quality of life and long-term sequelae.</p><p><strong>Methods: </strong>We conducted a systematic literature review and searched key databases (including MEDLINE, EMBASE, Web of Science, Scopus) for original articles on model-based full economic evaluations of COVID-19 drug treatments. Studies focussing on vaccines, diagnostic techniques and non-pharmaceutical interventions were excluded. The search was last rerun on 22 July 2023. Results were narratively synthesised in tabular form. Several aspects were categorised into rubrics to enable comparison across studies.</p><p><strong>Results: </strong>Of the 1047 records identified, 27 were included, and 23 studies (85.2%) differentiated patients by disease severity in the hospitalisation phase. Patients were differentiated by type of respiratory support, level of care management, a combination of both or symptoms. A Markov model was applied in 16 studies (59.3%), whether or not preceded by a decision tree or an epidemiological model. Most cost-utility analyses lacked the incorporation of COVID-19-specific health utility values. Of ten studies with a lifetime horizon, seven adjusted general population estimates to account for long-term sequelae (i.e. mortality, quality of life and costs), lasting for 1 year, 5 years, or a patient's lifetime. The most often reported parameter influencing the outcome of the analysis was related to treatment effectiveness.</p><p><strong>Conclusion: </strong>The results illustrate the variety in modelling approaches of COVID-19 drug treatments and address the need for a more standardized approach in model-based economic evaluations of infectious diseases such as COVID-19.</p><p><strong>Trial registry: </strong>Protocol registered in PROSPERO under CRD42023407646.</p>","PeriodicalId":19807,"journal":{"name":"PharmacoEconomics","volume":" ","pages":"633-647"},"PeriodicalIF":4.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11126513/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140898551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Comparison of the Psychometric Properties of the EQ-5D-Y-3L and EQ-5D-Y-5L Using Paediatric Multi-Instrument Comparison (P-MIC) Study Data. 使用儿科多工具比较 (P-MIC) 研究数据比较 EQ-5D-Y-3L 和 EQ-5D-Y-5L 的心理测量特性。
IF 4.4 3区 医学 Q1 Medicine Pub Date : 2024-06-01 Epub Date: 2024-05-15 DOI: 10.1007/s40273-024-01379-7
Mina Bahrampour, Nancy Devlin, Renee Jones, Kim Dalziel, Brendan Mulhern

Background: The EQ-5D-Y is a generic health-related quality of life (HRQoL) measure suitable for children and adolescents. There are two versions of the instrument, which differ in response levels: the three- (Y-3L) and five-level (Y-5L) versions. The Y-5L has been developed to improve the psychometric performance of the Y-3L.

Objective: This study aims to assess the psychometric properties of Y-5L and to compare the performance of Y-5L with Y-3L in separate self- and proxy-reported samples.

Methods: Both versions of the instrument were administered to children/adolescents (self-report) or caregivers (proxy-report) of Australian children aged 5-18 years. The data were gathered as part of the Australian Paediatric Multi-Instrument Comparison (P-MIC) study. The Y-5L and Y-3L were evaluated in terms of ceiling effects, criterion validity, inconsistency, informativity, and test-retest reliability in both proxy and self-complete populations.

Results: Overall, 5945 respondents completed both the Y-3L and Y-5L, with 2083 proxy and 3862 self-completed responses. Ceiling effects were lower in the Y-5L than the Y-3L. Items from the same domains show the strongest correlation for both samples. Regarding informativity, the Y-5L demonstrated more discriminatory power, indicated by having a higher Shannon diversity index in all domains of the Y-5L compared with the Y-3L. Test-retest showed fair agreement between responses at baseline and follow-up.

Conclusion: The Y-5L has demonstrated moderate validity and fair reliability for use in measuring HRQoL in children and adolescents, both when self-reported by children or proxy reported. Overall, Y-5L is a dependable and valid extension from the Y-3L.

背景:EQ-5D-Y 是一种适用于儿童和青少年的通用健康相关生活质量(HRQoL)测量方法。该工具有两个版本,在反应水平上有所不同:三水平(Y-3L)和五水平(Y-5L)版本。Y-5L 的开发是为了提高 Y-3L 的心理测量性能:本研究旨在评估 Y-5L 的心理测量特性,并比较 Y-5L 和 Y-3L 在不同的自我报告样本和代理报告样本中的表现:该工具的两个版本均由澳大利亚 5-18 岁儿童/青少年(自我报告)或照顾者(代理报告)使用。这些数据是作为澳大利亚儿科多工具比较(P-MIC)研究的一部分收集的。从天花板效应、标准效度、不一致性、信息量和测试-再测可靠性等方面对Y-5L和Y-3L进行了评估:共有 5945 名受访者同时完成了 Y-3L 和 Y-5L 测验,其中代理受访者有 2083 人,自填受访者有 3862 人。Y-5L的上限效应低于Y-3L。同一领域的项目在两个样本中显示出最强的相关性。在信息量方面,与 Y-3L 相比,Y-5L 在所有领域都具有更高的香农多样性指数,这表明 Y-5L 具有更强的判别能力。测试-重复测试表明,基线和随访时的回答具有相当的一致性:Y-5L在测量儿童和青少年的HRQoL时,无论是儿童自我报告还是代理报告,都显示出中等程度的有效性和相当的可靠性。总的来说,Y-5L 是 Y-3L 的可靠和有效的延伸。
{"title":"A Comparison of the Psychometric Properties of the EQ-5D-Y-3L and EQ-5D-Y-5L Using Paediatric Multi-Instrument Comparison (P-MIC) Study Data.","authors":"Mina Bahrampour, Nancy Devlin, Renee Jones, Kim Dalziel, Brendan Mulhern","doi":"10.1007/s40273-024-01379-7","DOIUrl":"10.1007/s40273-024-01379-7","url":null,"abstract":"<p><strong>Background: </strong>The EQ-5D-Y is a generic health-related quality of life (HRQoL) measure suitable for children and adolescents. There are two versions of the instrument, which differ in response levels: the three- (Y-3L) and five-level (Y-5L) versions. The Y-5L has been developed to improve the psychometric performance of the Y-3L.</p><p><strong>Objective: </strong>This study aims to assess the psychometric properties of Y-5L and to compare the performance of Y-5L with Y-3L in separate self- and proxy-reported samples.</p><p><strong>Methods: </strong>Both versions of the instrument were administered to children/adolescents (self-report) or caregivers (proxy-report) of Australian children aged 5-18 years. The data were gathered as part of the Australian Paediatric Multi-Instrument Comparison (P-MIC) study. The Y-5L and Y-3L were evaluated in terms of ceiling effects, criterion validity, inconsistency, informativity, and test-retest reliability in both proxy and self-complete populations.</p><p><strong>Results: </strong>Overall, 5945 respondents completed both the Y-3L and Y-5L, with 2083 proxy and 3862 self-completed responses. Ceiling effects were lower in the Y-5L than the Y-3L. Items from the same domains show the strongest correlation for both samples. Regarding informativity, the Y-5L demonstrated more discriminatory power, indicated by having a higher Shannon diversity index in all domains of the Y-5L compared with the Y-3L. Test-retest showed fair agreement between responses at baseline and follow-up.</p><p><strong>Conclusion: </strong>The Y-5L has demonstrated moderate validity and fair reliability for use in measuring HRQoL in children and adolescents, both when self-reported by children or proxy reported. Overall, Y-5L is a dependable and valid extension from the Y-3L.</p>","PeriodicalId":19807,"journal":{"name":"PharmacoEconomics","volume":" ","pages":"95-111"},"PeriodicalIF":4.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11168989/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140922190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
PharmacoEconomics Supplement : Advancing measurement of children's health-related quality of life - evidence from the QUOKKA (QUality OF Life in Kids: Key evidence to strengthen decisions in Australia) research program. 药物经济学补编 :推进儿童健康相关生活质量的测量--来自 QUOKKA(儿童生活质量:加强澳大利亚决策的关键证据)研究计划的证据。
IF 4.4 3区 医学 Q1 Medicine Pub Date : 2024-06-01 DOI: 10.1007/s40273-024-01384-w
{"title":"PharmacoEconomics Supplement : Advancing measurement of children's health-related quality of life - evidence from the QUOKKA (QUality OF Life in Kids: Key evidence to strengthen decisions in Australia) research program.","authors":"","doi":"10.1007/s40273-024-01384-w","DOIUrl":"10.1007/s40273-024-01384-w","url":null,"abstract":"","PeriodicalId":19807,"journal":{"name":"PharmacoEconomics","volume":" ","pages":"1"},"PeriodicalIF":4.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140898662","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparative Psychometric Performance of Common Generic Paediatric Health-Related Quality of Life Instrument Descriptive Systems: Results from the Australian Paediatric Multi-Instrument Comparison Study. 常见的通用儿科健康相关生活质量仪器描述系统的比较心理测量性能:来自澳大利亚儿科多仪器比较研究的结果。
IF 4.4 3区 医学 Q1 Medicine Pub Date : 2024-06-01 Epub Date: 2023-11-13 DOI: 10.1007/s40273-023-01330-2
Renee Jones, Rachel O'Loughlin, Xiuqin Xiong, Mina Bahrampour, Nancy Devlin, Harriet Hiscock, Gang Chen, Brendan Mulhern, Kim Dalziel

Objective: The aim of this study was to compare the psychometric performance of common generic paediatric health-related quality-of-life instrument descriptive systems (PedsQL generic core 4.0, EQ-5D-Y-3L, EQ-5D-Y-5L, Child Health Utility 9D [CHU9D], Assessment of Quality of Life 6D [AQoL-6D], and Health Utilities Index Mark 3 [HUI3]) by child age, report type, and health status.

Methods: Data for children aged 5-18 years were from the Australian Paediatric Multi-Instrument Comparison study. Ceiling effects, test-retest reliability, known-group validity, convergent and divergent validity, and responsiveness were assessed in the total sample and by child age (5-12 years vs 13-18 years), report type (self- vs proxy report), and health status. Instruments were scored using an exploratory level sum score (LSS) approach.

Results: Survey data were available for 5945 children, with follow-up data available for 2346 children. The EQ-5D-Y-3L demonstrated ceiling effects. The PedsQL, EQ-5D-Y-3L, EQ-5D-Y-5L, and CHU9D demonstrated acceptable test-retest reliability. All instruments demonstrated known-group, convergent, and divergent validity. The EQ-5D-Y-3L, EQ-5D-Y-5L, and CHU9D demonstrated responsiveness to improvements in health and the PedsQL, EQ-5D-Y-3L, EQ-5D-Y-5L, and CHU9D to worsening health. The AQoL-6D and HUI3 had inconclusive test-retest reliability and responsiveness evidence due to small sample size. Importantly, ceiling effects, test-retest reliability and responsiveness varied by subgroup.

Conclusion: Results reflect instrument performance using LSSs, which may differ to utility scores. In the total sample, the EQ-5D-Y-5L and CHU9D descriptive systems demonstrated evidence of good performance (i.e., meeting prespecified criteria) across all psychometric attributes tested. Performance varied by child age and report type, indicating room for considerations by population and study.

目的:本研究的目的是按儿童年龄、报告类型和健康状况比较常见的通用儿科健康相关生活质量工具描述系统(PedsQL generic core 4.0、EQ-5D-Y-3L、EQ-5D-Y-5L、儿童健康效用9D [CHU9D]、生活质量评估6D [aql -6D]和健康效用指数标记3 [HUI3])的心理测量表现。方法:5-18岁儿童的数据来自澳大利亚儿科多仪器比较研究。以总样本、儿童年龄(5-12岁vs 13-18岁)、报告类型(自我报告vs代理报告)和健康状况评估天花板效应、重测信度、已知组效度、收敛效度和发散效度以及反应性。使用探索性水平和评分(LSS)方法对仪器进行评分。结果:获得调查资料5945例,随访资料2346例。EQ-5D-Y-3L演示了天花板效果。PedsQL、EQ-5D-Y-3L、EQ-5D-Y-5L和CHU9D表现出可接受的重测可靠性。所有工具均显示已知组效度、收敛效度和发散效度。EQ-5D-Y-3L、EQ-5D-Y-5L和CHU9D表现出对健康改善的反应性,而PedsQL、EQ-5D-Y-3L、EQ-5D-Y-5L和CHU9D表现出对健康恶化的反应性。由于样本量小,aql - 6d和HUI3的重测信度和响应性证据不确定。重要的是,天花板效应、重测信度和反应性因亚组而异。结论:使用lss的结果反映了仪器的性能,可能与效用评分不同。在总样本中,EQ-5D-Y-5L和CHU9D描述系统在所有心理测量属性测试中表现出良好的性能(即满足预先指定的标准)。表现因儿童年龄和报告类型而异,表明人口和研究的考虑空间。
{"title":"Comparative Psychometric Performance of Common Generic Paediatric Health-Related Quality of Life Instrument Descriptive Systems: Results from the Australian Paediatric Multi-Instrument Comparison Study.","authors":"Renee Jones, Rachel O'Loughlin, Xiuqin Xiong, Mina Bahrampour, Nancy Devlin, Harriet Hiscock, Gang Chen, Brendan Mulhern, Kim Dalziel","doi":"10.1007/s40273-023-01330-2","DOIUrl":"10.1007/s40273-023-01330-2","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to compare the psychometric performance of common generic paediatric health-related quality-of-life instrument descriptive systems (PedsQL generic core 4.0, EQ-5D-Y-3L, EQ-5D-Y-5L, Child Health Utility 9D [CHU9D], Assessment of Quality of Life 6D [AQoL-6D], and Health Utilities Index Mark 3 [HUI3]) by child age, report type, and health status.</p><p><strong>Methods: </strong>Data for children aged 5-18 years were from the Australian Paediatric Multi-Instrument Comparison study. Ceiling effects, test-retest reliability, known-group validity, convergent and divergent validity, and responsiveness were assessed in the total sample and by child age (5-12 years vs 13-18 years), report type (self- vs proxy report), and health status. Instruments were scored using an exploratory level sum score (LSS) approach.</p><p><strong>Results: </strong>Survey data were available for 5945 children, with follow-up data available for 2346 children. The EQ-5D-Y-3L demonstrated ceiling effects. The PedsQL, EQ-5D-Y-3L, EQ-5D-Y-5L, and CHU9D demonstrated acceptable test-retest reliability. All instruments demonstrated known-group, convergent, and divergent validity. The EQ-5D-Y-3L, EQ-5D-Y-5L, and CHU9D demonstrated responsiveness to improvements in health and the PedsQL, EQ-5D-Y-3L, EQ-5D-Y-5L, and CHU9D to worsening health. The AQoL-6D and HUI3 had inconclusive test-retest reliability and responsiveness evidence due to small sample size. Importantly, ceiling effects, test-retest reliability and responsiveness varied by subgroup.</p><p><strong>Conclusion: </strong>Results reflect instrument performance using LSSs, which may differ to utility scores. In the total sample, the EQ-5D-Y-5L and CHU9D descriptive systems demonstrated evidence of good performance (i.e., meeting prespecified criteria) across all psychometric attributes tested. Performance varied by child age and report type, indicating room for considerations by population and study.</p>","PeriodicalId":19807,"journal":{"name":"PharmacoEconomics","volume":" ","pages":"39-55"},"PeriodicalIF":4.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11169028/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"89719190","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparing Generic Paediatric Health-Related Quality-of-Life Instruments: A Dimensionality Assessment Using Factor Analysis. 比较通用的儿科健康相关生活质量工具:使用因子分析进行维度评估。
IF 4.4 3区 医学 Q1 Medicine Pub Date : 2024-06-01 Epub Date: 2024-05-31 DOI: 10.1007/s40273-024-01382-y
Mina Bahrampour, Renee Jones, Kim Dalziel, Nancy Devlin, Brendan Mulhern

Background: Widely used generic instruments to measure paediatric health-related quality of life (HRQoL) include the EQ-5D-Y-5L, Child Health Utility 9 Dimension (CHU-9D), Paediatric Quality of Life Inventory (PedsQL) and Health Utilities Index (HUI). There are similarities and differences in the content of these instruments, but there is little empirical evidence on how the items they contain relate to each other, and to an overarching model of HRQoL derived from their content.

Objective: This study aimed to explore the dimensionality of the instruments using exploratory factor analysis (EFA).

Methods: Data from the Australian Paediatric Multi-Instrument Comparison (P-MIC) Study were used. EQ-5D-Y-5L, CHU-9D, PedsQL and HUI data were collected via proxy or child self-report data. EFA was used to investigate the underlying domain structure and measurement relationship. Items from the four instruments were pooled and domain models were identified for self- and proxy-reported data. The number of factors was determined based on eigenvalues greater than 1. A correlation cut-off of 0.32 was used to determine item loading on a given factor, with cross-loading also considered. Oblique rotation was used.

Results: Results suggest a six-factor structure for the proxy-reported data, including emotional functioning, pain, daily activities, physical functioning, school functioning, and senses, while the self-report data revealed a similar seven-factor structure, with social functioning emerging as an additional factor.

Conclusion: We provide evidence of differences and similarities between paediatric HRQoL instruments and the aspects of health being measured by these instruments. The results identified slight differences between self- and proxy-reported data in the relationships among items within the resulting domains.

背景:广泛使用的测量儿科健康相关生活质量(HRQoL)的通用工具包括 EQ-5D-Y-5L、儿童健康效用 9 维度(CHU-9D)、儿科生活质量量表(PedsQL)和健康效用指数(HUI)。这些工具的内容既有相似之处,也有不同之处,但关于这些工具所包含的项目之间的关系,以及根据其内容得出的 HRQoL 总体模型的关系,却鲜有实证证据:本研究旨在使用探索性因子分析(EFA)来探索工具的维度:方法:使用澳大利亚儿科多工具比较研究(P-MIC)的数据。EQ-5D-Y-5L、CHU-9D、PedsQL 和 HUI 数据通过代理数据或儿童自我报告数据收集。采用 EFA 方法研究基本领域结构和测量关系。对四种工具中的项目进行了汇总,并确定了自我报告和代理报告数据的领域模型。根据大于 1 的特征值确定因子的数量。相关性临界值为 0.32,用于确定特定因子上的项目负荷,同时也考虑交叉负荷。采用斜向旋转法:结果表明,代理报告数据具有六因子结构,包括情绪功能、疼痛、日常活动、身体功能、学校功能和感官,而自我报告数据显示了类似的七因子结构,其中社会功能是一个额外的因子:我们提供了儿科 HRQoL 工具与这些工具所测量的健康方面之间的异同证据。结果表明,自我报告数据和代理报告数据在所产生的领域内各项目之间的关系略有不同。
{"title":"Comparing Generic Paediatric Health-Related Quality-of-Life Instruments: A Dimensionality Assessment Using Factor Analysis.","authors":"Mina Bahrampour, Renee Jones, Kim Dalziel, Nancy Devlin, Brendan Mulhern","doi":"10.1007/s40273-024-01382-y","DOIUrl":"10.1007/s40273-024-01382-y","url":null,"abstract":"<p><strong>Background: </strong>Widely used generic instruments to measure paediatric health-related quality of life (HRQoL) include the EQ-5D-Y-5L, Child Health Utility 9 Dimension (CHU-9D), Paediatric Quality of Life Inventory (PedsQL) and Health Utilities Index (HUI). There are similarities and differences in the content of these instruments, but there is little empirical evidence on how the items they contain relate to each other, and to an overarching model of HRQoL derived from their content.</p><p><strong>Objective: </strong>This study aimed to explore the dimensionality of the instruments using exploratory factor analysis (EFA).</p><p><strong>Methods: </strong>Data from the Australian Paediatric Multi-Instrument Comparison (P-MIC) Study were used. EQ-5D-Y-5L, CHU-9D, PedsQL and HUI data were collected via proxy or child self-report data. EFA was used to investigate the underlying domain structure and measurement relationship. Items from the four instruments were pooled and domain models were identified for self- and proxy-reported data. The number of factors was determined based on eigenvalues greater than 1. A correlation cut-off of 0.32 was used to determine item loading on a given factor, with cross-loading also considered. Oblique rotation was used.</p><p><strong>Results: </strong>Results suggest a six-factor structure for the proxy-reported data, including emotional functioning, pain, daily activities, physical functioning, school functioning, and senses, while the self-report data revealed a similar seven-factor structure, with social functioning emerging as an additional factor.</p><p><strong>Conclusion: </strong>We provide evidence of differences and similarities between paediatric HRQoL instruments and the aspects of health being measured by these instruments. The results identified slight differences between self- and proxy-reported data in the relationships among items within the resulting domains.</p>","PeriodicalId":19807,"journal":{"name":"PharmacoEconomics","volume":" ","pages":"81-94"},"PeriodicalIF":4.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11169043/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141180379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psychometric Performance Comparison of the Adapted versus Original Versions of the EQ-5D-Y-3L and -Y-5L in Proxy Respondents for 2- to 4-Year-Olds. 2 至 4 岁儿童 EQ-5D-Y-3L 和 -Y-5L 代理受访者改编版与原始版的心理测量性能比较。
IF 4.4 3区 医学 Q1 Medicine Pub Date : 2024-06-01 Epub Date: 2024-01-18 DOI: 10.1007/s40273-024-01350-6
Alexander van Heusden, Oliver Rivero-Arias, Michael Herdman, Harriet Hiscock, Nancy Devlin, Kim Dalziel

Introduction: Few preference-weighted instruments are available to measure health-related quality of life in young children (2-4 years of age). The EQ-5D-Y-3L and EQ-5D-Y-5L were recently modified for this purpose.

Objective: The aim of this study was to test the psychometric properties of these adapted versions for use with parent proxies of children aged 2-4 years and to compare their performance with the original versions. It was hypothesised that the adapted instrument wording would result in improved psychometric performance.

Methods: Survey data of children aged 2-4 years were obtained from the Australian Paediatric Multi-Instrument Comparison study. Distributional and psychometric properties tested included feasibility, convergence, distribution of level scores, ceiling effects, known-group validity (Cohen's D effect sizes for prespecified groups defined by the presence/absence of special healthcare needs [SHCNs]), test-retest reliability (intraclass correlation coefficients [ICCs]), and responsiveness (standardised response mean [SRM] effect sizes for changes in health). Level sum scores were used to provide summary outcomes. Supplementary analysis using utility scores (from the Swedish EQ-5D-Y-3L value set) were conducted for the adapted and original EQ-5D-Y-3L, and no value sets were available for the EQ-5D-Y-5L.

Results: A total of 842 parents of children aged 2-4 years completed the survey. All instruments were easy to complete. There was strong convergence between the adapted and original EQ-5D-Y-3L and EQ-5D-Y-5L. The adapted EQ-5D-Y-3L and adapted EQ-5D-Y-5L showed more responses in the severe levels of the five EQ-5D-Y dimensions, particularly in the usual activity and mobility dimensions (EQ-5D-Y-5L: mobility level 1: adapted n = 478 [83%], original n = 253 [94%]; mobility level 4/5: adapted n = 17 [2.9%], original n = 4 [1.5%)]). The difference in the distribution of responses was more evident in children with SHCNs. Assessment of known-group validity showed a greater effect size for the adapted EQ-5D-Y-3L and adapted EQ-5D-Y-5L compared with the original instruments (EQ-5D-Y-5L: adapted Cohen's D = 1.01, original Cohen's D = 0.83) between children with and without SHCNs. The adapted EQ-5D-Y-3L and adapted EQ-5D-Y-5L showed improved reliability at 4-week follow-up, with improved ICCs (EQ-5D-Y-5L: adapted ICC = 0.83, original ICC = 0.44). The responsiveness of all instruments moved in the hypothesised direction for better or worse health at follow-up. Probability of superiority analysis showed little/no differences between the adapted and original EQ-5D-Y-3L and EQ-5D-Y-5L. Supplementary psychometric analysis of the adapted and original EQ-5D-Y-3L using utilities showed comparable findings with analyses using level sum scores.

Conclusions: The findings suggest improved psychometric performance of the adapted version of

介绍:用于测量幼儿(2-4 岁)健康相关生活质量的偏好加权工具寥寥无几。为此,最近对 EQ-5D-Y-3L 和 EQ-5D-Y-5L 进行了修改:本研究的目的是测试这些改编版本在用于 2-4 岁儿童家长代理人时的心理测量特性,并将其表现与原始版本进行比较。研究假设,改编后的问卷措辞将提高心理测量性能:2-4岁儿童的调查数据来自澳大利亚儿科多工具比较研究。测试的分布和心理测量学特性包括可行性、趋同性、水平得分的分布、上限效应、已知组有效性(根据是否有特殊医疗保健需求[SHCNs]对预先设定的组别进行的科恩D效应大小)、重测可靠性(类内相关系数[ICCs])和响应性(健康变化的标准化响应均值[SRM]效应大小)。水平总分用于提供汇总结果。使用效用评分(来自瑞典 EQ-5D-Y-3L 值集)对改编版和原始 EQ-5D-Y-3L 进行了补充分析,EQ-5D-Y-5L 没有值集:共有 842 名 2-4 岁儿童的家长完成了调查。所有工具均易于完成。改编后的 EQ-5D-Y-3L 和 EQ-5D-Y-5L 与原来的 EQ-5D-Y-3L 非常接近。改编版 EQ-5D-Y-3L 和改编版 EQ-5D-Y-5L 在 EQ-5D-Y 五个维度的严重程度上显示出更多的回答,尤其是在通常活动和行动能力维度上(EQ-5D-Y-5L:行动能力 1 级:改编版 n = 478 [83%],原始版 n = 253 [94%];行动能力 4/5 级:改编版 n = 17 [2.9%],原始版 n = 4 [1.5%)])。回答分布的差异在SHCN儿童中更为明显。已知组有效性评估显示,与原始工具相比,改编版 EQ-5D-Y-3L 和改编版 EQ-5D-Y-5L 在患有和未患有 SHCN 的儿童中具有更大的效应量(EQ-5D-Y-5L:改编版 Cohen's D = 1.01,原始 Cohen's D = 0.83)。改编后的 EQ-5D-Y-3L 和改编后的 EQ-5D-Y-5L 在 4 周的随访中显示出更高的可靠性,ICC 也有所提高(EQ-5D-Y-5L:改编后的 ICC = 0.83,原始 ICC = 0.44)。在随访时,所有工具的反应性都朝着健康状况改善或恶化的假设方向发展。优越性概率分析显示,改编后的 EQ-5D-Y-3L 和 EQ-5D-Y-5L 与原版几乎没有差异。使用效用对改编后的 EQ-5D-Y-3L 和原始 EQ-5D-Y-3L 进行的心理测量学补充分析表明,其结果与使用水平总分进行的分析结果相当:结论:研究结果表明,与原始版本相比,改编版 EQ-5D-Y-3L 和 EQ-5D-Y-5L 在 2-4 岁儿童中的心理测量性能有所提高。
{"title":"Psychometric Performance Comparison of the Adapted versus Original Versions of the EQ-5D-Y-3L and -Y-5L in Proxy Respondents for 2- to 4-Year-Olds.","authors":"Alexander van Heusden, Oliver Rivero-Arias, Michael Herdman, Harriet Hiscock, Nancy Devlin, Kim Dalziel","doi":"10.1007/s40273-024-01350-6","DOIUrl":"10.1007/s40273-024-01350-6","url":null,"abstract":"<p><strong>Introduction: </strong>Few preference-weighted instruments are available to measure health-related quality of life in young children (2-4 years of age). The EQ-5D-Y-3L and EQ-5D-Y-5L were recently modified for this purpose.</p><p><strong>Objective: </strong>The aim of this study was to test the psychometric properties of these adapted versions for use with parent proxies of children aged 2-4 years and to compare their performance with the original versions. It was hypothesised that the adapted instrument wording would result in improved psychometric performance.</p><p><strong>Methods: </strong>Survey data of children aged 2-4 years were obtained from the Australian Paediatric Multi-Instrument Comparison study. Distributional and psychometric properties tested included feasibility, convergence, distribution of level scores, ceiling effects, known-group validity (Cohen's D effect sizes for prespecified groups defined by the presence/absence of special healthcare needs [SHCNs]), test-retest reliability (intraclass correlation coefficients [ICCs]), and responsiveness (standardised response mean [SRM] effect sizes for changes in health). Level sum scores were used to provide summary outcomes. Supplementary analysis using utility scores (from the Swedish EQ-5D-Y-3L value set) were conducted for the adapted and original EQ-5D-Y-3L, and no value sets were available for the EQ-5D-Y-5L.</p><p><strong>Results: </strong>A total of 842 parents of children aged 2-4 years completed the survey. All instruments were easy to complete. There was strong convergence between the adapted and original EQ-5D-Y-3L and EQ-5D-Y-5L. The adapted EQ-5D-Y-3L and adapted EQ-5D-Y-5L showed more responses in the severe levels of the five EQ-5D-Y dimensions, particularly in the usual activity and mobility dimensions (EQ-5D-Y-5L: mobility level 1: adapted n = 478 [83%], original n = 253 [94%]; mobility level 4/5: adapted n = 17 [2.9%], original n = 4 [1.5%)]). The difference in the distribution of responses was more evident in children with SHCNs. Assessment of known-group validity showed a greater effect size for the adapted EQ-5D-Y-3L and adapted EQ-5D-Y-5L compared with the original instruments (EQ-5D-Y-5L: adapted Cohen's D = 1.01, original Cohen's D = 0.83) between children with and without SHCNs. The adapted EQ-5D-Y-3L and adapted EQ-5D-Y-5L showed improved reliability at 4-week follow-up, with improved ICCs (EQ-5D-Y-5L: adapted ICC = 0.83, original ICC = 0.44). The responsiveness of all instruments moved in the hypothesised direction for better or worse health at follow-up. Probability of superiority analysis showed little/no differences between the adapted and original EQ-5D-Y-3L and EQ-5D-Y-5L. Supplementary psychometric analysis of the adapted and original EQ-5D-Y-3L using utilities showed comparable findings with analyses using level sum scores.</p><p><strong>Conclusions: </strong>The findings suggest improved psychometric performance of the adapted version of ","PeriodicalId":19807,"journal":{"name":"PharmacoEconomics","volume":" ","pages":"129-145"},"PeriodicalIF":4.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11169041/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139491774","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
PharmacoEconomics
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1